Resmed Inc (RMD) Files Form 4 Insider Selling : James Hollingshead Sells 4,458 Shares

Resmed Inc (RMD): James Hollingshead , President, Americas of Resmed Inc sold 4,458 shares on Jun 15, 2016. The Insider selling transaction was reported by the company on Jun 16, 2016 to the Securities and Exchange Commission. The shares were sold at $59.40 per share for a total value of $264,827.03 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 16, 2016, James Hollingshead (President, Americas) sold 4,458 shares at $59.40 per share price.On Jun 8, 2016, Peter C Farrell (director) sold 20,000 shares at $59.82 per share price.Also, On Jun 6, 2016, David Pendarvis (Chief Administrative Officer) sold 6,000 shares at $59.41 per share price.On May 17, 2016, Michael J. Farrell (Chief Executive Officer) sold 5,975 shares at $57.63 per share price.

Shares of ResMed (RMD) ended Wednesday, Jun 15, 2016 session in red amid volatile trading. The shares closed down -0.6 points or -1.01% at $58.98 with 5,13,265 shares getting traded. Post opening the session at $59.84, the shares hit an intraday low of $58.93 and an intraday high of $60.01 and the price vacillated in this range throughout the day. The company has a market cap of $8,281 M and the number of outstanding shares has been calculated to be 14,04,09,810 shares. The 52-week high of ResMed is $61.23 and the 52-week low is $48.99.

ResMed Money Flow Index Chart

Company has been under the radar of several Street Analysts.ResMed is Upgraded by Macquarie to Neutral. Earlier the firm had a rating of Underperform on the company shares. The Rating was issued on Apr 28, 2016.ResMed is Downgraded by Piper Jaffray to Neutral. Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Apr 27, 2016.ResMed is Resumed by Barclays to Underweight and the brokerage firm has set the Price Target at $55. The Rating was issued on Apr 7, 2016.

ResMed Inc. is engaged in the development manufacturing distribution and marketing of medical products for the diagnosis treatment and management of respiratory disorders with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders including airflow generators diagnostic products mask systems headgear and other accessories. It produces continuous positive airway pressure variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape AirSense 10 Elite AirSense 10 CPAP S9 VPAP S S9 VPAP ST S9 VPAP Adapt S9 VPAP ST-A S9 VPAP COPD and AirCurve 10 V Auto among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX Swift FX for Her Mirage FX for Her Pixi Pediatric Mask Quattro FX for Her Swift FX Bella Swift FX Nano AirFit N10 and Apnealink Air.

Leave a Reply

ResMed - Is it time to Sell?

Top Brokerage Firms are advising their investors on ResMed. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.